Integra LifeSciences Holdings Corporation (NASDAQ:IART) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The firm presently has a $57.00 price target on the life sciences company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 10.10% from the stock’s current price.

According to Zacks, “Over the last six months, Integra Lifesciences has been trading above the broader industry. Moreover, the strong year over year increase in revenue on the back of solid performance of its Orthopedics and Tissue Technologies’ segment buoys optimism. We believe the company’s recent product diversification bolstered investors’ confidence, thereby boosting the stock price further. On the flip side, the company exited the second quarter of 2017 on somewhat disappointing note with earnings in line with the estimates and revenues missing the mark. We are concerned about the currency headwind that is expected to affect Integra’s financial performance in the rest of 2017. Also, contraction in adjusted operating margin and adjusted gross margin adds to the woes.”

Other equities research analysts have also issued reports about the stock. Oppenheimer Holdings, Inc. set a $60.00 target price on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research report on Saturday, June 24th. UBS AG reiterated a “buy” rating and set a $60.00 target price (up from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Friday, June 9th. Jefferies Group LLC restated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a report on Sunday, September 10th. Cantor Fitzgerald set a $65.00 price objective on shares of Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a report on Wednesday, July 26th. Finally, Barclays PLC restated an “equal weight” rating and issued a $53.00 price objective (up from $47.00) on shares of Integra LifeSciences Holdings Corporation in a report on Tuesday, September 12th. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $54.45.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded down 0.37% during trading on Tuesday, reaching $51.58. 71,467 shares of the company traded hands. The firm’s 50-day moving average is $50.60 and its 200-day moving average is $49.08. Integra LifeSciences Holdings Corporation has a 12-month low of $37.71 and a 12-month high of $56.42. The stock has a market capitalization of $4.03 billion, a PE ratio of 62.90 and a beta of 0.71.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The business had revenue of $282.16 million during the quarter, compared to analyst estimates of $283.58 million. During the same period in the previous year, the business posted $0.40 earnings per share. Integra LifeSciences Holdings Corporation’s revenue for the quarter was up 13.2% on a year-over-year basis. On average, equities analysts predict that Integra LifeSciences Holdings Corporation will post $1.90 earnings per share for the current fiscal year.

WARNING: This story was first posted by Marea Informative and is the sole property of of Marea Informative. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at http://www.mareainformativa.com/integra-lifesciences-holdings-corporation-iart-rating-increased-to-buy-at-zacks-investment-research/117301/.

In other news, Director Barbara B. Hill bought 5,050 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were bought at an average cost of $49.33 per share, with a total value of $249,116.50. Following the completion of the purchase, the director now directly owns 44,772 shares in the company, valued at $2,208,602.76. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Donald E. Morel, Jr. bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The stock was purchased at an average cost of $49.25 per share, for a total transaction of $492,500.00. Following the completion of the purchase, the director now owns 29,612 shares of the company’s stock, valued at $1,458,391. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 17,550 shares of company stock worth $864,842. 21.50% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of IART. BlackRock Inc. increased its stake in shares of Integra LifeSciences Holdings Corporation by 307,726.8% in the first quarter. BlackRock Inc. now owns 7,455,564 shares of the life sciences company’s stock worth $314,104,000 after buying an additional 7,453,142 shares during the period. Vanguard Group Inc. increased its stake in shares of Integra LifeSciences Holdings Corporation by 116.7% in the first quarter. Vanguard Group Inc. now owns 5,656,048 shares of the life sciences company’s stock worth $238,289,000 after buying an additional 3,046,488 shares during the period. Capital Research Global Investors increased its stake in shares of Integra LifeSciences Holdings Corporation by 227.0% in the second quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock worth $212,441,000 after buying an additional 2,705,488 shares during the period. Champlain Investment Partners LLC increased its stake in shares of Integra LifeSciences Holdings Corporation by 125.2% in the first quarter. Champlain Investment Partners LLC now owns 4,438,760 shares of the life sciences company’s stock worth $187,005,000 after buying an additional 2,468,145 shares during the period. Finally, FMR LLC increased its stake in shares of Integra LifeSciences Holdings Corporation by 44.1% in the first quarter. FMR LLC now owns 7,615,884 shares of the life sciences company’s stock worth $320,857,000 after buying an additional 2,329,710 shares during the period. 84.90% of the stock is currently owned by institutional investors.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Stock Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related stocks with our FREE daily email newsletter.